Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | PTAFR | P25105 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074507 | 1.00 | MEN1 (0.48) | MEN1KMT2AKDM4CPTAFRL3MBTL1 | |
| SCHEMBL32667257 | 0.97 | MEN1 (0.48) | MEN1KMT2AKDM4CPTAFRL3MBTL1 | |
| SCHEMBL4079349 | 0.91 | KDM4C (0.49) | MEN1KMT2AKDM4CPTAFRL3MBTL1 | |
| SCHEMBL4078714 | 0.91 | KDM4C (0.49) | MEN1KMT2AKDM4CPTAFRL3MBTL1 | |
| SCHEMBL22032193 | 0.87 | KDM4C (0.43) | MEN1KMT2AKDM4CPTAFRL3MBTL1 | |
| SCHEMBL1002925 | 0.86 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8844164 | 0.86 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13953674 | 0.86 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL30416895 | 0.85 | MEN1 (0.53) | MEN1KMT2AKDM4CPTAFRL3MBTL1 | |
| SCHEMBL4074819 | 0.84 | KDM4C (0.46) | MEN1KMT2AKDM4CPTAFRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1970064-A1 | Silicon-derivatives for pet-imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1911452-A1 | Silicon-derivates for PET-Imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
| EP-1908472-A1 | Silicon derivatives for PET imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035215-A1 | RADIOFLUORINATION | AFF2, AFF1, NUTF2 | MEN1 20/4885KMT2A 2045/4885KDM4C 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.